Published in Drug Week, November 11th, 2005
The first three ALS patients in the initial six-patient cohort received 40 mg of AEOL 10150 or placebo twice-daily (80 mg/day total) for 6 days, followed by a single injection of 40 mg on the seventh day, and, based on initial observations, there have been no serious adverse events.
Following the completion of the second half of the first cohort (i.e. the second three ALS patients), it is planned that two additional...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.